PE-22-28
Preclinical ResearchPE-22-28
A novel synthetic peptide targeting TREK-1 potassium channels. Researched for rapid antidepressant effects with a unique mechanism distinct from SSRIs.
Dose
Varies in research; common range is 0.1-1 mg/kg in animal models.
Route
SubQ injection, Nasal spray
Cycle
Typically 2-4 weeks in antidepressant research models.
Storage
Cold and dark storage (e.g., -20°C).
What is PE-22-28?
PE-22-28 is a novel synthetic peptide under investigation for its potential rapid antidepressant effects. Its mechanism of action is distinct from traditional antidepressants, primarily involving the inhibition of TREK-1 potassium channels. This modulation is believed to influence neuronal excitability and neurotransmitter release, including serotonin, leading to antidepressant and anxiolytic-like effects observed in preclinical models. Research also explores its potential in cognitive enhancement and neuroprotection. The peptide has been studied via both subcutaneous injection and intranasal administration.
Key Benefits
- Antidepressant research potential
- Rapid onset vs traditional antidepressants
- Unique TREK-1 mechanism
- Cognitive protection
- Potential anxiety reduction
Mechanism of Action
- Inhibits TREK-1 potassium channels
- Modulates serotonergic neurotransmission
- Different pathway from SSRIs and SNRIs
Best For
- Depression research
- Mood research
- Neurological health
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
848.0 g/mol (calculated for sequence Leu-Tyr-Phe-Ala-Leu-Val-Asp-Arg)
Length
8
Type
Synthetic Peptide
Amino acid sequence
LYFALVDR
Leu-Tyr-Phe-Ala-Leu-Val-Asp-Arg
Research Indications
Depression
Researched for its rapid antidepressant effects, distinct from traditional serotonergic pathways, through TREK-1 channel inhibition.
Anxiety
Preclinical studies suggest anxiolytic-like effects, potentially linked to its neuromodulatory actions.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Investigate rapid antidepressant effects via subcutaneous injection | 0.5-1 mg/kg | Daily | Subcutaneous (SubQ) |
| Assess antidepressant/anxiolytic effects via intranasal administration | 0.1-0.3 mg/kg | Daily | Nasal spray |
| Evaluate neuroprotective potential in stress models | 0.2-0.5 mg/kg | Every other day | Subcutaneous (SubQ) |
| Study long-term effects on mood and cognition | 0.5 mg/kg | Daily | Subcutaneous (SubQ) |
| Dose-response study for antidepressant-like behaviors | 0.1, 0.3, 0.5, 1.0 mg/kg | Single dose or daily for 7 days | Subcutaneous (SubQ) |
Research protocols for PE-22-28 are still evolving, and timing can be highly variable depending on the specific research objective and model.
Peptide Interactions
- Monitor Combination
SSRIs (Selective Serotonin Reuptake Inhibitors)
PE-22-28 acts via a distinct mechanism (TREK-1 inhibition), but both modulate serotonergic systems. Combination effects are not fully understood and should be carefully monitored in research settings.
- Monitor Combination
SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
Similar to SSRIs, SNRIs affect monoaminergic systems. While PE-22-28's mechanism is different, potential synergistic or adverse interactions require careful investigation.
- Use Caution
Alcohol
General caution with CNS-active compounds. Alcohol can depress CNS function, potentially altering or masking the effects of PE-22-28, or leading to unexpected interactions.
- Use Caution
Other CNS Depressants (e.g., Benzodiazepines)
Combination with other CNS depressants may lead to additive effects, requiring careful observation and protocol adjustment.
- Monitor Combination
Stimulants
Interactions with stimulants are largely unexplored. Potential for counteracting effects or unexpected physiological responses should be considered.
How to Reconstitute
- 1Gather materials: PE-22-28 lyophilized powder, bacteriostatic water for injection (BWFI) or sterile saline, sterile syringe, and alcohol wipes.
- 2Remove the cap from the PE-22-28 vial and wipe the rubber stopper with an alcohol wipe.
- 3Draw the desired amount of diluent (e.g., 1-2 mL for commonly studied concentrations) into a sterile syringe.
- 4Slowly inject the diluent into the vial, aiming the stream against the inner wall of the vial, not directly onto the powder.
- 5Gently swirl the vial to dissolve the powder. Do not shake vigorously, as this can degrade the peptide.
- 6Once fully dissolved, the solution should be clear. Store the reconstituted solution according to instructions.
Care should be taken to ensure sterile technique during reconstitution to prevent contamination. The diluent choice can impact stability.
What to Expect
- Within days to a week: Preclinical research suggests potential rapid onset of antidepressant-like effects, possibly observed as improved behavioral responses in relevant models.
- Weeks 1-2: Continued assessment for sustained antidepressant and anxiolytic effects; potential for modulation of mood-related behaviors.
- Weeks 2-4: Evaluation of longer-term effects on mood, cognitive function, and potential neuroprotective properties.
- Throughout the research period: Monitoring for any observed changes in general behavior, activity levels, and stress responses.
- Note: Observable effects will depend heavily on the specific research model, dose, and administration route used.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Very limited safety data | Unknown | Unknown |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.